Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30174219 | 0.90 | CSNK1E (0.34) | PIK3C3RIPK1 | |
| SCHEMBL25529249 | 0.82 | PRKDC (0.35) | MKNK1MKNK2RIPK1KCNK3KDM4E | |
| SCHEMBL25529258 | 0.80 | L3MBTL1 (0.36) | KCNK3KDM4E | |
| SCHEMBL25529260 | 0.76 | SMN1; SMN2 (0.36) | KCNK3KDM4E | |
| SCHEMBL27218043 | 0.75 | HDAC3 (0.31) | KDM4E | |
| SCHEMBL25529250 | 0.74 | RIPK1 (0.36) | PIK3C3MKNK1MKNK2RIPK1 | |
| SCHEMBL27218052 | 0.74 | PSMB5 (0.31) | — | |
| SCHEMBL25529262 | 0.74 | GRIN2B (0.33) | KCNK3KDM4E | |
| SCHEMBL30174224 | 0.72 | CSNK1E (0.36) | MKNK1MKNK2RIPK1KDM4E | |
| SCHEMBL30174235 | 0.70 | ALDH1A1 (0.34) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| CN-115605478-A | Compounds and methods of use | 埃克塞里艾克西斯公司（US） | 2023-01-13 | — | — | CN | disclosed |
| EP-4110779-A1 | COMPOUNDS AND METHODS OF USE | Exelixis, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | PRKACB, PRKACA, PRKX | PIK3C3 151/4885MKNK1 171/4885MKNK2 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.